Low-Flow, Low-Gradient Aortic Stenosis: True Severe or Pseudosevere?
A 68-year-old retired teacher has progressive exertional dyspnoea (NYHA III) and one episode of exertional syncope. He has a bicuspid aortic valve diagnosed 15 years ago and mild hypertension. Echocardiography shows LVEF 38%, aortic valve area 0.9 cm² (indexed 0.45 cm²/m²), mean gradient 30 mmHg, peak velocity 3.0 m/s, stroke volume index 28 mL/m², and no more than mild aortic regurgitation. Dobutamine stress echocardiography at 20 µg/kg/min raises LVEF to 46% and stroke volume index to 40 mL/m², peak velocity to 3.8 m/s and mean gradient to 44 mmHg, while the calculated valve area remains 0.88 cm². The aortic root measures 44 mm. Coronary angiography shows no obstructive disease. The STS-PROM is 2.1%, frailty assessment is normal, and the heart team is considering both surgical and transcatheter approaches. He asks whether his valve is really tight and whether he can wait until he is older.
1. Interpret the rest and dobutamine echocardiographic data. Is this true severe stenosis or pseudosevere stenosis, and how do you know?
Read the worked answer
This is true severe aortic stenosis with contractile reserve.
At rest he has low-flow, low-gradient AS: valve area below 1.0 cm², mean gradient below 40 mmHg, LVEF below 50% and a low stroke volume index of 28 mL/m². In this situation the gradient underestimates severity because flow is low; the diagnostic question is whether the valve is truly severely narrowed or merely appears so because the failing ventricle cannot generate enough flow to open it fully.
During dobutamine, stroke volume index rose from 28 to 40 mL/m² - more than the 20% increase that defines contractile reserve. Peak velocity rose from 3.0 to 3.8 m/s and mean gradient from 30 to 44 mmHg, while the calculated valve area stayed at 0.88 cm². If the valve were only moderately diseased (pseudosevere AS), the increase in flow would have opened the valve area above 1.0 cm². Because the area remained fixed and the gradient rose steeply with flow, the valve is genuinely severely stenotic. The rise in LVEF to 46% also shows that part of the LV dysfunction is afterload-related and potentially reversible.
Clinical weight. He is symptomatic with NYHA III dyspnoea and exertional syncope and has LVEF below 50%; both are class I indications for aortic valve replacement. Contractile reserve predicts a better operative outcome, but its absence would not by itself deny surgery.
2. If the dobutamine study had been non-diagnostic, what would you do next, and what else must be excluded as a cause of the low ejection fraction?
Read the worked answer
When stress echocardiography is inconclusive.
- Cardiac CT for valve calcium. A high Agatston calcium score in the aortic valve supports true severe stenosis in a low-flow state, whereas a low score in a patient with a small calculated valve area suggests pseudosevere disease. Calcium scoring is most useful when flow reserve is absent or the haemodynamics are discordant.
- Stroke volume assessment. Confirm the low-flow state with a measured LVOT diameter and Doppler stroke volume, and check for measurement error, atrial fibrillation, significant mitral regurgitation or anaemia, all of which alter flow and gradients.
- Alternative imaging. Consider cardiac MRI if echocardiographic windows are poor, and invasive haemodynamics with dobutamine if the non-invasive data remain contradictory.
Excluding other causes of LV dysfunction.
- Coronary disease: his angiogram is clean, but review for prior infarction and scar on MRI if the aetiology is unclear.
- Tachyarrhythmia, thyroid disease, alcohol and cardiotoxic drugs.
- Bicuspid aortopathy with associated coarctation, which can cause chronic afterload excess.
- Myocardial disease such as amyloidosis, which would change prognosis and surgical risk; look for discordant wall thickness, low voltage and suggestive MRI findings if suspicion exists.
A heart team decision should be made on the totality of data rather than on a single calculated valve area.
3. What intervention would you recommend, when, and what will you do about the 44 mm aortic root? Address the SAVR versus TAVI question explicitly.
Read the worked answer
Recommendation: surgical aortic valve replacement now, with a bioprosthesis, and no ascending aortic replacement at 44 mm.
Timing. He has symptomatic severe AS with LVEF below 50% - operating now is class I. Waiting until he is older is not safe: symptomatic severe AS with reduced EF carries a high risk of sudden death and progressive irreversible LV dysfunction, and his low STS score (2.1%) and normal frailty make early surgery favourable.
SAVR versus TAVI. At 68 with a low surgical risk, bicuspid anatomy and a dilated ascending aorta, surgery is preferred. TAVI is feasible in selected bicuspid valves but is associated with more paravalvular leak and uncertain long-term durability in younger patients, and it does not address the aorta. A bioprosthesis avoids lifelong anticoagulation; discuss the likelihood of future valve-in-valve intervention.
The aorta. A root of 44 mm does not meet the threshold for concomitant replacement. Intervention is generally considered at 50 mm or more in bicuspid aortopathy, or around 45 mm when additional risk factors are present. At surgery the team should inspect the aorta, and if it measures 45 mm or more with risk factors, or shows rapid growth, concomitant replacement becomes reasonable. Plan annual imaging of the residual aorta after surgery.
Perioperative points. Optimise blood pressure and treat any heart failure before surgery, and counsel about the small but real risk of prosthesis–patient mismatch given his body size.